A phase II study of neodjuvant chemoimmunotherapy followed by stereotactic radiotherapy/nelfinavir in patients with locally advanced CA125 expressing pancreatic adenocarcinoma

Authors :: Chandrakanth Are
Christopher F. Nicodemus
Madi Madiyalakan
Jane L. Meza
Jean L. Grem
Quan P. Ly
James K. Schwarz
Chi Lin
James C. Padussis
Michael A. Hollingsworth
Lyudmyla Derby Berim
Source :: Journal of Clinical Oncology. 36:e16202-e16202
Publication Year :: 2018
Publisher :: American Society of Clinical Oncology (ASCO), 2018.
Abstract: e16202Background: CA-125, a tumor marker expressed in > 50% pancreatic adenocarcinoma (PAC), was targeted with oregovomab (O), a monoclonal antibody currently in development as chemoimmunotherapy (...

Subjects :: Cancer Research
business.industry
medicine.drug_class
Phases of clinical research
Monoclonal antibody
medicine.disease
Nelfinavir
Oncology
Chemoimmunotherapy
Oregovomab
Cancer research
Medicine
Adenocarcinoma
In patient
business
medicine.drug
Tumor marker

Full Text Access

Tools